Westlake Chemical Partners Eyes Rebound After Turnaround Year

Westlake Chemical Partners LP ((WLKP)) has held its Q4 earnings call. Read on for the main highlights of the call.

Westlake Chemical Partners’ latest earnings call painted a mixed picture for investors. Management stressed the resilience of its fee-based model, steady distributions, and strong balance sheet, but also acknowledged a sizable hit from 2025 turnaround activity that dragged down full-year earnings, distributable cash flow, and coverage. The tone was measured yet cautiously optimistic about a rebound in 2026.

Consistent Distributions and Long Track Record

Westlake Partners emphasized its income reliability, pointing to 46 consecutive quarterly distributions since its 2014 IPO. The latest quarterly payout was set at $0.4714 per unit and paid in late February 2026, representing a 71% increase from the original minimum quarterly distribution.

Stable, Fee-Based Model and Contract Renewal

The partnership’s core strength remains its fixed-margin ethylene sales agreement, which covers roughly 95% of annual plant output and insulates results from commodity price swings. Management underscored that OpCo has renewed this agreement with its sponsor through 2027 on unchanged terms, effectively locking in predictable earnings.

Quarterly Distributable Cash Flow Improvement

Despite a tough full year, the fourth quarter showed improvement in cash generation. Distributable cash flow for Q4 2025 rose to $19 million, or $0.53 per unit, about 26.7% higher than the $15 million recorded in the prior-year quarter, largely because maintenance capital spending was lower due to timing.

Strong Leverage Metrics and Liquidity Cushion

Leverage remained a key positive as the consolidated leverage ratio stayed below 1x, giving the partnership financial flexibility. At year-end, Westlake reported $68 million in consolidated cash and investments with its sponsor and an operating surplus of roughly $74 million, supporting ongoing distributions.

Solid Consolidated Earnings and Sales Base

On a consolidated basis including OpCo, the business continued to generate substantial earnings and revenue. Westlake posted $84 million of consolidated net income in the fourth quarter on net sales of $323 million, and full-year 2025 consolidated net income reached $299 million, underscoring the scale of the underlying ethylene platform.

No Planned Turnarounds in 2026

Management highlighted that 2026 will not include planned major turnarounds, unlike 2025. With plants expected to run more steadily, Westlake anticipates higher production and sales volumes, which should help restore distributable cash flow and coverage ratios closer to historical norms.

Full-Year Net Income Decline from Turnaround

At the partnership level, 2025 earnings took a clear step down due to the heavy maintenance year. Net income fell to $49 million, or $1.38 per unit, a drop of about 21% from $62 million in 2024, as lower production and sales volumes weighed on results.

MLP Distributable Cash Flow Drop and Weak Coverage

Full-year MLP distributable cash flow mirrored that earnings decline, sliding to $53 million from $67 million a year earlier. This pushed the 2025 distribution coverage ratio down to 0.8x, below the comfort level many income investors prefer and meaning distributions exceeded that year’s cash generation.

Turnaround’s Direct Hit to Production and Cash

The planned turnaround at the Pecan ethylene facility was the main culprit behind the weaker metrics. Reduced production and sales volumes during the outage not only cut into net income and distributable cash flow but also forced the partnership to tap investment and operating reserves to bridge the period.

Capital Spending and Investment Account Drawdown

OpCo invested heavily in the asset base, with 2025 capital expenditures reaching $79 million, largely tied to the turnaround program. To fund this, management drew on its investment management account, reducing that balance but noting it expects to rebuild reserves in years without major maintenance.

Dependence on Sponsor and Limited Upside

While the fixed-margin structure with sponsor Westlake provides stability, management acknowledged it also caps upside from favorable ethylene markets. Future growth, likely via asset drop-downs, would probably require a mix of new debt or equity, which could dilute existing unitholders or increase leverage.

Coverage Below Historical Target Levels

The partnership’s 2025 coverage shortfall stands out against its longer-term record. Management noted that historically cumulative coverage has averaged about 1.1x, but the turnaround year dragged full-year coverage down to 0.8x, highlighting the sensitivity of metrics to heavy maintenance cycles.

Guidance and Outlook for Recovery

Looking ahead, Westlake Partners expects a cleaner 2026, with no planned turnarounds, supporting stronger plant utilization and higher volumes. Management anticipates distributable cash flow and coverage to recover toward and ultimately above the historical 1.1x target, helped by low leverage, solid liquidity, and a renewed fixed-margin contract that runs through 2027.

Westlake Chemical Partners’ call left investors weighing a tough maintenance year against a clearer path ahead. While 2025 saw lower earnings, weaker coverage, and reserve drawdowns, the partnership maintains a long distribution track record, conservative leverage, and high earnings visibility, setting up 2026 as a potential rebound year for cash flow and coverage metrics.